Safety and its clinical curative effect of intra abdominal implantation of sustained releasing fluorouracil in patients with colorectal cancer

doi:10.3877/cma.j.issn.1674-0793.2013.05.010

Abstract

Abstract:

Objective

To study the safety and its clinical curative effect of intra abdominal implantation of sustained releasing fluorouracil.

Methods

One hundred and fifty-eight patients in the Department of First Pathology confirmed as II/ III stage colorectal cancer were randomly divided into three groups, A (implantation group), B (celiac infusion group) and C (control group). Group A was given radical surgical operation + intra abdominal implantation of sustained releasing fluorouracil; Group B radical surgical operation + celiac hot infusion chemotherapy; Group C radical surgery + traditional chemotherapy. The postoperative complications, first chemotherapy toxicity, 2-year and 5-year survival rate of the three groups were compared respectively.

Results

There were equivalent complications in Group A and B, their bone marrow suppression and liver function damage were lighter than Group C. There were no significant differences between the 2-year or 5-year disease-free and overall survival rate of Group A and B, but the disease-free survival rates of Group A and B were higher than that of Group C, with statistical significance, P<0.05. Three groups showed no significant difference in the 2-year overall survival rate, disease-free survival rate of 5-year and 5-year overall survival rate.

Conclusion

Intra abdominal implantation of sustained releasing fluorouracil is safe; it may reduce the 2-year recurrence, but can not improve immediate and long-term survival rate.

Key words: Colorectal, Fluorouracil, Drug therapy, Surgery

Zhi-dong LIN, Sheng-ming MAO, Ju-yuan BU, Jin-lin ZOU. Safety and its clinical curative effect of intra abdominal implantation of sustained releasing fluorouracil in patients with colorectal cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2013, 07(05): 370-373.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2013.05.010

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2013/V07/I05/370

Figures/Tables 3

References 8

1	陈佳平. 胃癌术后复发的诊断与治疗. 中国普外基础与临床杂志, 2004, 11(2): 104-106.
2	徐大志，耿其荣，林桐榆, 等. 腹腔化疗在进展期胃癌根治术后治疗作用新评价. 第四军医大学学报, 2009, 30(5): 443-446.
3	朱莉菲，黄伟翼，陈栋晖, 等. 进展期胃癌术后早期腹腔温热灌注化疗疗效的临床研究.中国肿瘤, 2008, 17(9): 810-812.
4	周军，周载平，陈双, 等. 进展期胃癌术中低渗温热腹腔化疗联合生物蛋白胶缓释氟尿嘧啶植入的临床研究[J/CD]. 中华普通外科学文献:电子版, 2008, 2(2): 128-131.
5	李沛雨. 直肠癌病人术中植入5-氟尿嘧啶缓释剂的安全性及疗效研究. 外科理论与实践, 2009, 14(1): 51-54.
6	周益龙，蒋松琪，黄建, 等. 直肠癌根治术中植入5-氟尿嘧啶缓释剂45例临床研究.南通大学学报(医学版), 2007, 27(6): 520-521.
7	Fisher B, Gunduz N, Saffer EA. Influence of the interal between primary tumor removal and chemotherapy on kinetic sand growth of metastases. Cancer Res, 1983, 43(4): 1488-1492.
8	陈黎，王筝，陈锦发, 等. 术中使用缓释型5-FU对于进展期结肠癌的疗效研究. 外科理论与实践, 2007, 12(5): 499-501.

组别	手术前后Ⅱ期符合率	手术前后Ⅲ期符合率
A组（植入组）	83.33%（20/24），4例为Ⅲ期	86.21%（25/29），4例为Ⅱ期
B组（腹腔灌注组）	84.00%（21/25），4例为Ⅲ期	83.33%（25/30），5例为Ⅱ期
C组（对照组）	79.17%（19/24），5例为Ⅲ期	89.65%（26/29），3例为Ⅱ期

组别	手术前后Ⅱ期符合率	手术前后Ⅲ期符合率
A组（植入组）	83.33%（20/24），4例为Ⅲ期	86.21%（25/29），4例为Ⅱ期
B组（腹腔灌注组）	84.00%（21/25），4例为Ⅲ期	83.33%（25/30），5例为Ⅱ期
C组（对照组）	79.17%（19/24），5例为Ⅲ期	89.65%（26/29），3例为Ⅱ期

术后不良反应	A组(53例)	B组（53例）	C组（52例）
恶心、呕吐	46(86.80)	44(83.02)^b	33(63.46) ^c
腹痛	5(9.43)	3(5.66) ^a	1(1.92) ^c
腹胀	1(1.89)	4(7.54) ^a	1(1.92) ^d
腹泻	1(1.89)	2(3.77)^b	0(0.00) ^d
肠梗阻	1(1.89)	1(1.89) ^b	1(1.92) ^d
吻合口漏	2 (3.77)	1(1.89)^b	1(1.92) ^d
肠穿孔	0(0.00)	0(0.00) ^b	0(0.00) ^d
腹腔出血	0(0.00)	0(0.00) ^b	0(0.00) ^d
切口感染	2 (3.77)	3(5.66) ^b	1(1.92) ^d
白细胞减少	2 (3.77)	2(3.77) ^b	7(13.46) ^c
肝功能异常	2 (3.77)	2(3.77) ^b	11(21.15) ^c

术后不良反应	A组(53例)	B组（53例）	C组（52例）
恶心、呕吐	46(86.80)	44(83.02)^b	33(63.46) ^c
腹痛	5(9.43)	3(5.66) ^a	1(1.92) ^c
腹胀	1(1.89)	4(7.54) ^a	1(1.92) ^d
腹泻	1(1.89)	2(3.77)^b	0(0.00) ^d
肠梗阻	1(1.89)	1(1.89) ^b	1(1.92) ^d
吻合口漏	2 (3.77)	1(1.89)^b	1(1.92) ^d
肠穿孔	0(0.00)	0(0.00) ^b	0(0.00) ^d
腹腔出血	0(0.00)	0(0.00) ^b	0(0.00) ^d
切口感染	2 (3.77)	3(5.66) ^b	1(1.92) ^d
白细胞减少	2 (3.77)	2(3.77) ^b	7(13.46) ^c
肝功能异常	2 (3.77)	2(3.77) ^b	11(21.15) ^c

生存率	A组(53例)	B组（53例）	C组（52例）
2年无瘤生存率	40(75.5)	39(73.6) ^a	33(63.5)^b
2年生存率	44(83.0)	42(78.7)^a	40(76.9)^c
5年无瘤生存率	24(45.3)	22(41.5) ^a	22(42.3)^c
5年总生存率	29(54.7)	30(56.6) ^a	28(53.8) ^c

Please choose a citation manager

Content to export